Jamp Nitrofurantoin: Formulary list price $0.2927/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2927 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98541 · Verify on the e-Formulary ↗ (DIN 02495503)
Source record
DIN 02495503: Jamp Nitrofurantoin
Raw flags: sec3=Y
Item: 083600013; group id 127; item number 0212; lccId None; manufacturer id JPC
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2927; ministry $0.2927
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495503
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98541Interchangeable products
Macrodantin · DIN 01997637 · not recorded
Teva-Nitrofurantoin · DIN 02231015 · $0.2927
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495503
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Nitrofurantoin · DIN 02231015 · 50mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Nitrofurantoin · DIN 02231015
Manufacturer: Teva Canada Limited; listing date 1998-12-31
Daily cost (source): $1.1708
Health Canada: Marketed since 2011-10-19 · brand TEVA-NITROFURANTOIN · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 50 MG · company Teva canada limited · schedule Prescription
Teva-Nitrofurantoin: Formulary list price $0.2927/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2927 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50295 · Verify on the e-Formulary ↗ (DIN 02231015)
Source record
DIN 02231015: Teva-Nitrofurantoin
Raw flags: sec3=Y
Item: 083600013; group id 127; item number 0212; lccId None; manufacturer id TEV
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.2927; ministry $0.2927
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231015
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50295Interchangeable products
Jamp Nitrofurantoin · DIN 02495503 · $0.2927
Macrodantin · DIN 01997637 · not recorded
Shortage status: resolved shortage (ended 2025-07-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231015
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nitrofurantoin · DIN 00319511 · 50mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nitrofurantoin · DIN 00319511
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Daily cost (source): $0.6812
Health Canada: Marketed since 2010-11-29 · brand NITROFURANTOIN · ATC J01XE01 NITROFURANTOIN · form Tablet · route Oral · ingredients NITROFURANTOIN 50 MG · company Aa pharma inc · schedule Prescription
Nitrofurantoin: Formulary list price $0.1703/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1703 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2094 · Verify on the e-Formulary ↗ (DIN 00319511)
Source record
DIN 00319511: Nitrofurantoin
Raw flags: sec3=Y
Item: 083600015; group id 127; item number 0214; lccId None; manufacturer id AAP
Source form: Tab; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.1703; ministry $0.1703
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00319511
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2094Interchangeable products
Nifuran · DIN 00017086 · not recorded
Shortage status: resolved shortage (ended 2025-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00319511
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Nitrofurantoin · DIN 02495511 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Nitrofurantoin · DIN 02495511
Manufacturer: Jamp Pharma Corporation; listing date 2025-05-30
Daily cost (source): $2.1996
Health Canada: Marketed since 2025-04-02 · brand JAMP NITROFURANTOIN · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Jamp pharma corporation · schedule Prescription
Jamp Nitrofurantoin: Formulary list price $0.5499/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5499 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98542 · Verify on the e-Formulary ↗ (DIN 02495511)
Source record
DIN 02495511: Jamp Nitrofurantoin
Raw flags: sec3=Y
Item: 083600012; group id 127; item number 0213; lccId None; manufacturer id JPC
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.5499; ministry $0.5499
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495511
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98542Interchangeable products
Macrodantin · DIN 01997645 · not recorded
Teva-Nitrofurantoin · DIN 02231016 · $0.5499
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02495511
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Nitrofurantoin · DIN 02231016 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Nitrofurantoin · DIN 02231016
Manufacturer: Teva Canada Limited; listing date 1998-12-31
Daily cost (source): $2.1996
Health Canada: Marketed since 2011-10-19 · brand TEVA-NITROFURANTOIN · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Teva canada limited · schedule Prescription
Teva-Nitrofurantoin: Formulary list price $0.5499/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5499 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50297 · Verify on the e-Formulary ↗ (DIN 02231016)
Source record
DIN 02231016: Teva-Nitrofurantoin
Raw flags: sec3=Y
Item: 083600012; group id 127; item number 0213; lccId None; manufacturer id TEV
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.5499; ministry $0.5499
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231016
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50297Interchangeable products
Jamp Nitrofurantoin · DIN 02495511 · $0.5499
Macrodantin · DIN 01997645 · not recorded
Shortage status: resolved shortage (ended 2025-07-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231016
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nitrofurantoin · DIN 00312738 · 100mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nitrofurantoin · DIN 00312738
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Daily cost (source): $0.9088
Health Canada: Marketed since 2011-10-25 · brand NITROFURANTOIN · ATC J01XE01 NITROFURANTOIN · form Tablet · route Oral · ingredients NITROFURANTOIN 100 MG · company Aa pharma inc · schedule Prescription
Nitrofurantoin: Formulary list price $0.2272/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2272 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2093 · Verify on the e-Formulary ↗ (DIN 00312738)
Source record
DIN 00312738: Nitrofurantoin
Raw flags: sec3=Y
Item: 083600008; group id 127; item number 0215; lccId None; manufacturer id AAP
Source form: Tab; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.2272; ministry $0.2272
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00312738
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2093Interchangeable products
Nifuran · DIN 00017094 · not recorded
Shortage status: resolved shortage (ended 2025-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00312738
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nifuran · PIN 00017086 · 50mg · tablet
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nifuran · DIN 00017086
Manufacturer: Paul Maney Labs., Division of Canapharm Ind. Inc.; listing date 2006-06-15
Daily cost (source): $0.6812
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 00017086: Nifuran
Raw flags: notABenefit=Y, sec3=Y
Item: 083600015; group id 127; item number 0214; lccId None; manufacturer id MAN
Source form: Tab; strength: 50mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00017086
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Nitrofurantoin · DIN 00319511 · $0.1703
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00017086
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Nifuran · PIN 00017094 · 100mg · tablet
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Nifuran · DIN 00017094
Manufacturer: Paul Maney Labs., Division of Canapharm Ind. Inc.; listing date 2006-06-15
Daily cost (source): $0.9088
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 00017094: Nifuran
Raw flags: notABenefit=Y, sec3=Y
Item: 083600008; group id 127; item number 0215; lccId None; manufacturer id MAN
Source form: Tab; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00017094
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Nitrofurantoin · DIN 00312738 · $0.2272
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00017094
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Macrodantin · DIN 01997637 · 50mg · capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.Discontinued 2010-07-07 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Macrodantin · DIN 01997637
Manufacturer: Proctor & Gamble Pharmaceuticals Canada, Inc.; listing date 1996-10-01
Daily cost (source): $1.1708
Health Canada: Cancelled post market since 2010-07-07 · brand MACRODANTIN (50 MG) · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 50 MG · company Procter & gamble pharmaceuticals canada inc · schedule Prescription
Macrodantin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14010 · Verify on the e-Formulary ↗ (DIN 01997637)
Source record
DIN 01997637: Macrodantin
Raw flags: notABenefit=Y, sec3=Y
Item: 083600013; group id 127; item number 0212; lccId None; manufacturer id PGP
Source form: Cap; strength: 50mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01997637
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14010Interchangeable products
Jamp Nitrofurantoin · DIN 02495503 · $0.2927
Teva-Nitrofurantoin · DIN 02231015 · $0.2927
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01997637
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Macrodantin · DIN 01997645 · 100mg · capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.Discontinued 2010-07-07 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Macrodantin · DIN 01997645
Manufacturer: Proctor & Gamble Pharmaceuticals Canada, Inc.; listing date 1996-10-01
Daily cost (source): $2.1996
Health Canada: Cancelled post market since 2010-07-07 · brand MACRODANTIN (100 MG) · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Procter & gamble pharmaceuticals canada inc · schedule Prescription
Macrodantin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14004 · Verify on the e-Formulary ↗ (DIN 01997645)
Source record
DIN 01997645: Macrodantin
Raw flags: notABenefit=Y, sec3=Y
Item: 083600012; group id 127; item number 0213; lccId None; manufacturer id PGP
Source form: Cap; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01997645
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14004Interchangeable products
Jamp Nitrofurantoin · DIN 02495511 · $0.5499
Teva-Nitrofurantoin · DIN 02231016 · $0.5499
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01997645
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
NITROFURANTOIN MONO/MICRO CRYSTALS
3 general benefit · 1 not a benefit
Other products in the same Health Canada class (J01X) — coverage varies; not interchangeable
Fosfomycin tromethamine (Monurol): general benefit
Auro-Nitrofurantoin BID · DIN 02466392 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Nitrofurantoin BID · DIN 02466392
Manufacturer: Auro Pharma Inc.; listing date 2024-07-31
Health Canada: Marketed since 2020-09-09 · brand AURO-NITROFURANTOIN BID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Auro pharma inc · schedule Prescription
Auro-Nitrofurantoin BID: Formulary list price $0.3067/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3067 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95474 · Verify on the e-Formulary ↗ (DIN 02466392)
Source record
DIN 02466392: Auro-Nitrofurantoin BID
Raw flags: sec3=Y
Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id AUR
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.3067; ministry $0.3067
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466392
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95474Interchangeable products
Jamp Nitrofurantoin BID · DIN 02544954 · $0.3067
MacroBID · DIN 02063662 · not recorded
PMS-Nitrofurantoin BID · DIN 02455676 · $0.3067
Shortage status: resolved shortage (ended 2025-03-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466392
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Nitrofurantoin BID · DIN 02544954 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Nitrofurantoin BID · DIN 02544954
Manufacturer: Jamp Pharma Corporation; listing date 2025-04-30
Health Canada: Marketed since 2025-02-18 · brand JAMP NITROFURANTOIN BID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Jamp pharma corporation · schedule Prescription
Jamp Nitrofurantoin BID: Formulary list price $0.3067/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3067 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103357 · Verify on the e-Formulary ↗ (DIN 02544954)
Source record
DIN 02544954: Jamp Nitrofurantoin BID
Raw flags: sec3=Y
Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id JPC
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.3067; ministry $0.3067
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02544954
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103357Interchangeable products
Auro-Nitrofurantoin BID · DIN 02466392 · $0.3067
MacroBID · DIN 02063662 · not recorded
PMS-Nitrofurantoin BID · DIN 02455676 · $0.3067
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544954
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Nitrofurantoin BID · DIN 02455676 · 100mg · capsule
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Nitrofurantoin BID · DIN 02455676
Manufacturer: Pharmascience Inc.; listing date 2018-07-31
Health Canada: Marketed since 2021-08-11 · brand PMS-NITROFURANTOIN BID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Pharmascience inc · schedule Prescription
PMS-Nitrofurantoin BID: Formulary list price $0.3067/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.3067 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94248 · Verify on the e-Formulary ↗ (DIN 02455676)
Source record
DIN 02455676: PMS-Nitrofurantoin BID
Raw flags: sec3=Y
Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id PMS
Source form: Cap; strength: 100mg
Recorded listing: General benefit
Source prices (unrounded): $0.3067; ministry $0.3067
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02455676
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94248Interchangeable products
Auro-Nitrofurantoin BID · DIN 02466392 · $0.3067
Jamp Nitrofurantoin BID · DIN 02544954 · $0.3067
MacroBID · DIN 02063662 · not recorded
Shortage status: active shortage (reported 2026-08-21, estimated to end 2027-01-05, last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02455676
Shortage record checked 2026-09-13T08:10:21.292534+00:00
MacroBID · DIN 02063662 · 100mg · capsule
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.Discontinued 2021-08-12 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
MacroBID · DIN 02063662
Manufacturer: Warner Chilcott Canada Co.; listing date 1996-12-19
Health Canada: Cancelled post market since 2021-08-12 · brand MACROBID · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 100 MG · company Allergan inc · schedule Prescription
MacroBID: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15173 · Verify on the e-Formulary ↗ (DIN 02063662)
Source record
DIN 02063662: MacroBID
Raw flags: notABenefit=Y, sec3=Y
Item: 083600018; group id 128; item number 0216; lccId None; manufacturer id WAR
Source form: Cap; strength: 100mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02063662
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15173Interchangeable products
Auro-Nitrofurantoin BID · DIN 02466392 · $0.3067
Jamp Nitrofurantoin BID · DIN 02544954 · $0.3067
PMS-Nitrofurantoin BID · DIN 02455676 · $0.3067
Shortage status: discontinued (2021-08-13, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02063662
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-08-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:36 Urinary Anti-Infectives) and how they are covered
Matched class: 08:36 Urinary Anti-Infectives
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: FOSFOMYCIN TROMETHAMINE
08:36 Urinary Anti-Infectives
1 Indications
NITROFURANTOIN (Nitrofurantoin tablets) is indicated for:
The treatment of pyelonephritis, pyelitis, and cystitis when due to susceptible organisms.
NITROFURANTOIN is not for the treatment of associated renal cortical or perinephric abscesses, nor in
prostatitis.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of
NITROFURANTOIN and other antibacterial drugs, NITROFURANTOIN should be used only to treat
infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and
susceptibility information are available, they should be considered in selecting or modifying antibacterial
therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to
the empiric selection of therapy.
1.1 Pediatrics
Pediatrics (< 1 month of age): Based on the data submitted and reviewed by Health Canada, the safety
and efficacy of NITROFURANTOIN in pediatric patients has not been established; therefore, Health
Canada has not authorized an indication for pediatric use. See 2 Contraindications.
1.2 Geriatrics
Geriatrics (>65 years of age): Evidence from clinical st…
https://pdf.hres.ca/dpd_pm/00080984.PDF
PM date: 2025-07-03
Source product: NITROFURANTOIN; DIN 00312738; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
pms-NITROFURANTOIN BID is indicated for the treatment of acute uncomplicated urinary
tract infections, e.g., cystitis, when due to susceptible strains of Escherichia coli, and
Staphylococcus saprophyticus.
pms-NITROFURANTOIN BID is not indicated for the treatment of associated renal cortical or
perinephric abscesses.
pms-NITROFURANTOIN BID is not indicated for therapy of any systemic infections or for use
in prostatitis.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of
pms-NITROFURANTOIN BID and other antibacterial drugs, pms-NITROFURANTOIN BID
pms-NITROFURANTOIN BID Product Monograph Page 2 of 21
should be used only to treat infections that are proven or strongly suspected to be caused by
susceptible bacteria. When culture and susceptibility information are available, they should be
considered in selecting or modifying antibacterial therapy. In the absence of such data, local
epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
https://pdf.hres.ca/dpd_pm/00057835.PDF
PM date: August 26, 2020
Source product: PMS-NITROFURANTOIN BID; DIN 02455676; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
PMS-Nitrofurantoin BID · DIN 02455676
Shortage status: active shortage (reported 2026-08-21, estimated to end 2027-01-05, last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02455676
For Nifuran, Macrodantin, MacroBID: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.